The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
Recruiting · NCT06717295 · Observational (researchers observe without assigning treatment) · Lead sponsor: Javier Toledo
View the official record on ClinicalTrials.gov →Interventions studied
DiNanoQ: A multi-cancer early detection (MCED) blood testDiNanoTrack: Therapeutic Response Monitoring Blood Test
What this trial is about
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. By analysing blood samples using artificial intelligence, the study seeks to create a safe, non-invasive method to enhance cancer diagnosis and monitor treatment responses over time.
Who can take part
Age range
40 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age: Adults aged 40 years or older.
- Confirmed diagnosis of one of the following common cancers: Non-Small Cell Lung Cancer (NSCLC), Glioblastoma Multiforme (GBM), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Breast Cancer, Prostate Cancer, Ovarian Cancer, Pancreatic Cancer.
Exclusion criteria
- Currently pregnant.
- Presence of any active infectious diseases.
- Use of anticoagulant or antiplatelet drugs within the past 2 weeks.
- Any medical or psychological conditions that may affect the participant's ability to comply with study procedures.
- Phase 2 ( Cancer Immuno-Profiling of Hematologic and Extracellular RNA - CIPHER)
- Inclusion Criteria:
- Adults aged 40 years or older.
- Confirmed diagnosis of: Hepatocellular Carcinoma (HCC), Non-Small Cell Lung Cancer (NSCLC)
- Willingness to provide blood samples at the specified intervals (baseline, 6 weeks, and 6 months post-therapy initiation).
- Exclusion Criteria:
- Presence of another malignancy unless it has been in remission for at least 5 years.
- Significant uncontrolled co-morbid conditions that may interfere with study participation or outcomes.
Where it is running
8 locations listed.
- Babraham Research Institute - Cambridge, United Kingdom
- Babraham Research Institute - Cambridge, United Kingdom
- NSIA- Lagos University Teaching Hospital Cancer Centre - Lagos, Nigeria
- NSIA- Lagos University Teaching Hospital Cancer Centre - Lagos, Nigeria
- Dysplasia Diagnostics Limited - London, United Kingdom
- Dysplasia Diagnostics Limited - London, United Kingdom
- Various Cancer Centres - Rosario, Argentina
- Various Cancer Centres - Rosario, Argentina